Vita Life Sciences Inkomsten in het verleden

Verleden criteriumcontroles 5/6

Vita Life Sciences is de winst gegroeid met een gemiddeld jaarlijks percentage van 19.8%, terwijl de Pharmaceuticals industrie de winst jaarlijks groeide met 35.1%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 14.1% per jaar. Het rendement op eigen vermogen van Vita Life Sciences is 19.3%, en het heeft een nettomarge van 11.9%.

Belangrijke informatie

19.8%

Groei van de winst

19.7%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie	31.2%
Inkomstengroei	14.1%
Rendement op eigen vermogen	19.3%
Nettomarge	11.9%
Laatste winstupdate	30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Opbrengsten en kosten

Hoe Vita Life Sciences geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

CHIA:VLS Opbrengsten, kosten en inkomsten (AUD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven
30 Jun 24	79	9	34
31 Mar 24	77	9	32
31 Dec 23	74	9	31
30 Sep 23	71	8	30
30 Jun 23	69	7	29
31 Mar 23	68	7	29
31 Dec 22	67	7	29
30 Sep 22	65	8	27
30 Jun 22	64	8	26
31 Mar 22	61	8	25
31 Dec 21	57	8	24
30 Sep 21	54	8	23
30 Jun 21	50	7	22
31 Mar 21	48	6	22
31 Dec 20	46	6	21
30 Sep 20	46	6	22
30 Jun 20	45	5	22
31 Mar 20	44	4	23
31 Dec 19	42	3	23
30 Sep 19	42	2	23
30 Jun 19	41	2	23
31 Mar 19	41	2	22
31 Dec 18	41	2	21
30 Sep 18	40	3	21
30 Jun 18	40	4	21
31 Mar 18	38	3	20
31 Dec 17	37	3	20
30 Sep 17	37	3	20
30 Jun 17	37	3	20
31 Mar 17	38	3	20
31 Dec 16	38	3	20
30 Sep 16	38	4	20
30 Jun 16	38	5	20
31 Mar 16	39	5	21
31 Dec 15	39	4	21
30 Sep 15	38	4	20
30 Jun 15	37	4	20
31 Mar 15	37	6	20
31 Dec 14	37	7	19
30 Sep 14	36	7	19
30 Jun 14	36	7	19
31 Mar 14	36	6	19
31 Dec 13	35	5	18

Kwaliteitswinsten: VLS heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: De huidige netto winstmarges (11.9%) VLS } zijn hoger dan vorig jaar (10.8%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: De winst van VLS is de afgelopen 5 jaar met 19.8% per jaar gegroeid.

Versnelling van de groei: De winstgroei van VLS over het afgelopen jaar ( 26.6% ) overtreft het 5-jarig gemiddelde ( 19.8% per jaar).

Winst versus industrie: De winstgroei VLS over het afgelopen jaar ( 26.6% ) overtrof de Pharmaceuticals -sector 26.6%.

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 19.3% ) van VLS wordt als laag beschouwd.

Vita Life Sciences Inkomsten in het verleden

Verleden criteriumcontroles 5/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Full year 2023 earnings released: EPS: AU$0.17 (vs AU$0.13 in FY 2022)

Full year 2022 earnings released: EPS: AU$0.13 (vs AU$0.16 in FY 2021)

Full year 2022 earnings released: EPS: AU$0.13 (vs AU$0.16 in FY 2021)

First half 2022 earnings released: EPS: AU$0.069 (vs AU$0.07 in 1H 2021)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

First half 2021 earnings released: EPS AU$0.07 (vs AU$0.058 in 1H 2020)

Recent updates

Less than half of directors are independent

Non-Executive Chairman recently sold AU$654k worth of stock

New minor risk - Insider selling

MD & Director recently sold AU$1.9m worth of stock

Upcoming dividend of AU$0.06 per share

Vita Life Sciences Limited, Annual General Meeting, May 15, 2024

Final dividend increased to AU$0.06

Full year 2023 earnings released: EPS: AU$0.17 (vs AU$0.13 in FY 2022)

Less than half of directors are independent

Vita Life Sciences Limited Provides Earnings Guidance for the Full Year Ending December 31, 2023

Less than half of directors are independent

Upcoming dividend of AU$0.03 per share at 3.7% yield

Less than half of directors are independent

Vita Life Sciences Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, 6 October 2023

Vita Life Sciences Limited Appoints Peter Osborne as an Independent Non-Executive Director

No independent directors

No independent directors

No independent directors

No independent directors

Full year 2022 earnings released: EPS: AU$0.13 (vs AU$0.16 in FY 2021)

Upcoming dividend of AU$0.033 per share at 3.9% yield

No independent directors

Full year 2022 earnings released: EPS: AU$0.13 (vs AU$0.16 in FY 2021)

No independent directors

No independent directors

No independent directors

No independent directors

Vita Life Sciences Provides Earnings Guidance for the Full Year Ending 31 December 2022

No independent directors

Less than half of directors are independent

Vita Life Sciences Limited Announces Board Changes, Effective 30 September 2022

Upcoming dividend of AU$0.028 per share

Vita Life Sciences Limited Declares Fully Franked Interim Dividend for the Six Months Ended June 30, 2022, Payable on 7 October 2022

First half 2022 earnings released: EPS: AU$0.069 (vs AU$0.07 in 1H 2021)

Less than half of directors are independent

Less than half of directors are independent

Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2022

Less than half of directors are independent

Upcoming dividend of AU$0.03 per share

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Less than half of directors are independent

Vita Life Sciences Limited Announces Dividend for Six Months Ended December 31, 2021, Payable on April 7, 2022

Less than half of directors are independent

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Upcoming dividend of AU$0.028 per share

First half 2021 earnings released: EPS AU$0.07 (vs AU$0.058 in 1H 2020)

Less than half of directors are independent

Less than half of directors are independent

Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2021

Upcoming Dividend of AU$0.015 Per Share

Earnings released

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Rendement op eigen vermogen

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden